Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody

Immunotherapy will significantly impact the standard of care in cancer treatment. Recent advances in nanotechnology can improve the efficacy of cancer immunotherapy. However, concerns regarding efficiency of cancer nanomedicine, complex tumor microenvironment, patient heterogeneity, and systemic immunotoxicity drive interest in more novel approaches to be developed. For this purpose, biomimetic nanoparticles are developed to make innovative changes in the delivery and biodistribution of immunotherapeutics. Biomimetic nanoparticles have several advantages that can advance the clinical efficacy of cancer immunotherapy. Thus there is a greater push toward the utilization of biomimetic nanotechnology for developing effective cancer immunotherapeutics that demonstrate increased specificity and potency. The recent works and state‐of‐the‐art strategies for anti‐tumor immunotherapeutics are highlighted here, and particular emphasis has been given to the applications of cell‐derived biomimetic nanotechnology for cancer immunotherapy.

show abstract

“…Thus it could further improve the biomimetic application of nanotechnology in personalized therapy. [ 134 ]…”

Section: Applications Of Cell‐derived Biomimetic Nanotechnology For Cmentioning

confidence: 99%

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Raza

Zafar

Zhang

et al. 2021

Adv Healthcare Materials

105

View full text Add to dashboard Cite

show abstract

“…P-aPDL1 was demonstrated to enable controlled delivery of PDL1 and potent recurrence inhibition on the post-surgical mouse models with melanoma and triple-negative breast carcinoma (TNBC). Han et al applied P-aPDL1 to inhibit tumor relapse and metastasis after thermal ablation 142. Photothermal therapy is limited because remnants of microtumors are often responsible for local recurrence and distant metastasis.…”

Section: Engineering Cells Via Chemical Bioconjugationmentioning

confidence: 99%

Advances in Engineering Cells for Cancer Immunotherapy

Shen

et al. 2019

Theranostics

View full text Add to dashboard Cite

Cancer immunotherapy aims to utilize the host immune system to kill cancer cells. Recent representative immunotherapies include T-cell transfer therapies, such as chimeric antigen receptor T cell therapy, antibody-based immunomodulator therapies, such as immune checkpoint blockade therapy, and cytokine therapies. Recently developed therapies leveraging engineered cells for immunotherapy against cancers have been reported to enhance antitumor efficacy while reducing side effects. Such therapies range from biologically, chemically and physically -engineered cells to bioinspired and biomimetic nanomedicines. In this review, advances of engineering cells for cancer immunotherapy are summarized, and prospects of this field are discussed.

show abstract

“…They can activate and attach to the injured area to prevent bleeding. Recently, platelets and platelet-derived EVs have been applied in cancer immunotherapy [31,[95][96][97]. As early as 2017, Wang et al [98] proposed using platelets as a carrier to modify anti-PD-L1 on the surface to prevent recurrence and metastasis after surgical removal of tumors.…”

Section: Plateletmentioning

confidence: 99%

“…It was verified on mice with B16F10 and 4T1 tumor models, and the results showed that the platform could effectively release the anti-PD-L1 antibody, and significantly prolonged the survival rate of mice after surgery, reducing the rate of cancer regeneration ( Figure 5). In another work, Han and co-workers [96] designed a platelet-based platform to deliver anti-PD-L1 checkpoint antibodies to inhibit tumor recurrence. Considering that platelets have good inflammation targeting ability, they hoped to apply anti-PD-L1 platelet monoclonal antibody to efficiently transport anti-PD-L1 antibody to the area of residual tumor ablation, thereby effectively inhibiting local tumor recurrence.…”

Section: Plateletmentioning

confidence: 99%

Cell-derived vesicles for delivery of cancer immunotherapy

Wang

2021

Exploration of Medicine

Self Cite

View full text Add to dashboard Cite

In recent years, cancer immunotherapy has received unprecedented attention due to the clinical achievements. The applications of biomedical engineering and materials science to cancer immunotherapy have solved the challenges caused by immunotherapy to a certain extent. Among them, cell-derived vesicles are natural biomaterials chosen as carriers or immune-engineering in view of their many unique advantages. This review will briefly introduce the recent applications of cell-derived vesicles for cancer immunotherapy.

show abstract

Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody

Cited by 72 publications

References 42 publications

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Advances in Engineering Cells for Cancer Immunotherapy

Cell-derived vesicles for delivery of cancer immunotherapy

Contact Info

Product

Resources

About